• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病相关肝细胞癌的全球流行病学:趋势、预测、危险因素和预防。

Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.

机构信息

Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore, Singapore.

Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

出版信息

Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):223-238. doi: 10.1038/s41575-020-00381-6. Epub 2020 Dec 21.

DOI:10.1038/s41575-020-00381-6
PMID:33349658
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8016738/
Abstract

One quarter of the global population is estimated to have nonalcoholic fatty liver disease (NAFLD). The incidence of nonalcoholic steatohepatitis (NASH) is projected to increase by up to 56% in the next 10 years. NAFLD is already the fastest growing cause of hepatocellular carcinoma (HCC) in the USA, France and the UK. Globally, the prevalence of NAFLD-related HCC is likely to increase concomitantly with the growing obesity epidemic. The estimated annual incidence of HCC ranges from 0.5% to 2.6% among patients with NASH cirrhosis. The incidence of HCC among patients with non-cirrhotic NAFLD is lower, approximately 0.1 to 1.3 per 1,000 patient-years. Although the incidence of NAFLD-related HCC is lower than that of HCC of other aetiologies such as hepatitis C, more people have NAFLD than other liver diseases. Urgent measures that increase global awareness and tackle the metabolic risk factors are necessary to reduce the impending burden of NAFLD-related HCC. Emerging evidence indicates that reduced immune surveillance, increased gut inflammation and gut dysbiosis are potential key steps in tumorigenesis. In this Review, we discuss the global epidemiology, projections and risk factors for NAFLD-related HCC, and propose preventive strategies to tackle this growing problem.

摘要

据估计,全球四分之一的人口患有非酒精性脂肪性肝病(NAFLD)。预计在未来 10 年内,非酒精性脂肪性肝炎(NASH)的发病率将增加高达 56%。NAFLD 已经成为美国、法国和英国肝细胞癌(HCC)增长最快的病因。在全球范围内,随着肥胖症的流行,NAFLD 相关 HCC 的患病率可能会相应增加。在 NASH 肝硬化患者中,HCC 的估计年发病率在 0.5%至 2.6%之间。在非肝硬化性 NAFLD 患者中,HCC 的发病率较低,约为每 1000 患者年 0.1 至 1.3 例。尽管 NAFLD 相关 HCC 的发病率低于丙型肝炎等其他病因引起的 HCC,但患有 NAFLD 的人比其他肝病患者多。必须采取增加全球认识和解决代谢危险因素的紧急措施,以减轻即将出现的 NAFLD 相关 HCC 的负担。新出现的证据表明,免疫监视减弱、肠道炎症和肠道菌群失调增加是肿瘤发生的潜在关键步骤。在这篇综述中,我们讨论了 NAFLD 相关 HCC 的全球流行病学、预测和危险因素,并提出了应对这一日益严重问题的预防策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1372/8016738/9a5720835ced/nihms-1666322-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1372/8016738/766832ebd087/nihms-1666322-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1372/8016738/03014a4946eb/nihms-1666322-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1372/8016738/9a5720835ced/nihms-1666322-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1372/8016738/766832ebd087/nihms-1666322-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1372/8016738/03014a4946eb/nihms-1666322-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1372/8016738/9a5720835ced/nihms-1666322-f0003.jpg

相似文献

1
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.非酒精性脂肪性肝病相关肝细胞癌的全球流行病学:趋势、预测、危险因素和预防。
Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):223-238. doi: 10.1038/s41575-020-00381-6. Epub 2020 Dec 21.
2
Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.非酒精性脂肪性肝病相关肝细胞癌:日益受到关注。
Indian J Med Res. 2019 Jan;149(1):9-17. doi: 10.4103/ijmr.IJMR_1456_17.
3
Hepatocellular carcinoma and non-alcoholic fatty liver disease.肝细胞癌与非酒精性脂肪性肝病。
Hepatol Int. 2019 Nov;13(6):688-694. doi: 10.1007/s12072-019-09995-8. Epub 2019 Nov 7.
4
Nonalcoholic fatty liver disease and hepatocellular carcinoma.非酒精性脂肪性肝病与肝细胞癌
Metabolism. 2016 Aug;65(8):1151-60. doi: 10.1016/j.metabol.2016.01.010. Epub 2016 Jan 23.
5
Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.非酒精性脂肪性肝病/非酒精性脂肪性肝炎与肝细胞癌。
Clin Liver Dis. 2018 Feb;22(1):201-211. doi: 10.1016/j.cld.2017.08.014.
6
From NASH to HCC: current concepts and future challenges.从 NASH 到 HCC:当前概念和未来挑战。
Nat Rev Gastroenterol Hepatol. 2019 Jul;16(7):411-428. doi: 10.1038/s41575-019-0145-7.
7
Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: A Problem of Growing Magnitude.非酒精性脂肪性肝病相关肝细胞癌:一个日益严重的问题。
Semin Liver Dis. 2015 Aug;35(3):304-17. doi: 10.1055/s-0035-1562949. Epub 2015 Sep 17.
8
Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets.肥胖、非酒精性脂肪性肝病和肝细胞癌:现状和治疗靶点。
Front Endocrinol (Lausanne). 2023 Jun 8;14:1148934. doi: 10.3389/fendo.2023.1148934. eCollection 2023.
9
Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.非肝硬化非酒精性脂肪性肝病和代谢综合征背景下的肝细胞癌:美国的经验
Dig Dis Sci. 2015 Oct;60(10):3142-8. doi: 10.1007/s10620-015-3821-7. Epub 2015 Aug 7.
10
Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.非酒精性脂肪性肝病和非酒精性脂肪性肝炎的流行病学:对肝移植的影响。
Transplantation. 2019 Jan;103(1):22-27. doi: 10.1097/TP.0000000000002484.

引用本文的文献

1
Global, regional, and national burden of NASH related liver cancer in adults aged 45 and above: an analysis from the GBD 2021 and forecast to 2050.45岁及以上成年人中与非酒精性脂肪性肝炎相关的肝癌的全球、区域和国家负担:来自全球疾病负担研究(GBD)2021的分析及到2050年的预测
Front Nutr. 2025 Aug 19;12:1651357. doi: 10.3389/fnut.2025.1651357. eCollection 2025.
2
Metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma: Challenges in clinical practice.代谢功能障碍相关脂肪性肝病与肝细胞癌:临床实践中的挑战
Clin Exp Hepatol. 2025 Jun;11(2):105-112. doi: 10.5114/ceh.2025.151618. Epub 2025 Jun 9.
3
Toxins to treatments: Impact of environmental pollutants, gut microbiota, and natural compounds on non-alcoholic fatty liver disease progression.

本文引用的文献

1
Epidemiology, clinical treatment patterns, and survival of hepatocellular carcinoma in Manitoba.曼尼托巴省肝细胞癌的流行病学、临床治疗模式及生存率
Can Liver J. 2020 Jun 4;3(2):194-202. doi: 10.3138/canlivj.2019-0015. eCollection 2020 Spring.
2
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.亚太肝病学会代谢相关性脂肪性肝病临床诊疗指南。
Hepatol Int. 2020 Dec;14(6):889-919. doi: 10.1007/s12072-020-10094-2. Epub 2020 Oct 1.
3
From NAFLD to MAFLD: Implications of a Premature Change in Terminology.
从毒素到治疗:环境污染物、肠道微生物群和天然化合物对非酒精性脂肪性肝病进展的影响
World J Hepatol. 2025 Aug 27;17(8):108772. doi: 10.4254/wjh.v17.i8.108772.
4
Cost-effectiveness of transient elastography for liver fibrosis screening in Thai patients with diabetes mellitus.瞬时弹性成像技术用于泰国糖尿病患者肝纤维化筛查的成本效益分析
World J Gastroenterol. 2025 Aug 28;31(32):110333. doi: 10.3748/wjg.v31.i32.110333.
5
Quantification of liver steatosis of metabolic dysfunction-associated steatotic liver disease based on body composition analysis.基于身体成分分析的代谢功能障碍相关脂肪性肝病肝脂肪变性定量分析
Sci Rep. 2025 Aug 30;15(1):31982. doi: 10.1038/s41598-025-17396-1.
6
Mitochondrial dysfunction in hepatocellular carcinoma: from metabolism to targeted therapies.肝细胞癌中的线粒体功能障碍:从代谢到靶向治疗
Mol Cell Biochem. 2025 Aug 30. doi: 10.1007/s11010-025-05377-x.
7
Multidimensional insights into exosomes in hepatocellular carcinoma: from genesis to clinical application.肝细胞癌中外泌体的多维见解:从起源到临床应用
Front Immunol. 2025 Aug 13;16:1628573. doi: 10.3389/fimmu.2025.1628573. eCollection 2025.
8
Immune metabolic changes identify causal candidate genes and enable diagnostic frameworks in MAFLD.免疫代谢变化可识别因果候选基因,并助力非酒精性脂肪性肝病的诊断框架。
Sci Rep. 2025 Aug 28;15(1):31751. doi: 10.1038/s41598-025-17406-2.
9
Reduced Platelet Aggregation and Plasma Cytokine Levels Mitigate Progressive Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).血小板聚集和血浆细胞因子水平降低可减轻进展性代谢功能障碍相关脂肪性肝病(MASLD)。
J Inflamm Res. 2025 Aug 20;18:11385-11400. doi: 10.2147/JIR.S533707. eCollection 2025.
10
Burden of liver cancer in the European region from 1990 to 2021: a sub-analysis of the global burden of disease study.1990年至2021年欧洲地区肝癌负担:全球疾病负担研究的子分析
Ann Med Surg (Lond). 2025 May 30;87(7):4053-4065. doi: 10.1097/MS9.0000000000003433. eCollection 2025 Jul.
从非酒精性脂肪性肝病到代谢相关脂肪性肝病:术语过早改变的影响。
Hepatology. 2021 Mar;73(3):1194-1198. doi: 10.1002/hep.31420. Epub 2021 Feb 6.
4
Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study.2019-2030 年加拿大非酒精性脂肪性肝病负担:建模研究。
CMAJ Open. 2020 Jun 9;8(2):E429-E436. doi: 10.9778/cmajo.20190212. Print 2020 Apr-Jun.
5
Annual report to the nation on the status of cancer, part I: National cancer statistics.国家癌症报告:癌症现状年度报告第一部分:国家癌症统计数据。
Cancer. 2020 May 15;126(10):2225-2249. doi: 10.1002/cncr.32802. Epub 2020 Mar 12.
6
MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.MAFLD:代谢相关脂肪性肝病的共识驱动命名建议。
Gastroenterology. 2020 May;158(7):1999-2014.e1. doi: 10.1053/j.gastro.2019.11.312. Epub 2020 Feb 8.
7
AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.AGA 临床实践更新:非酒精性脂肪性肝病患者肝细胞癌的筛查和监测:专家综述。
Gastroenterology. 2020 May;158(6):1822-1830. doi: 10.1053/j.gastro.2019.12.053. Epub 2020 Jan 30.
8
PNPLA3 Genotype and Risk of Liver and All-Cause Mortality.PNPLA3基因分型与肝脏及全因死亡率风险
Hepatology. 2020 Mar;71(3):777-779. doi: 10.1002/hep.31113. Epub 2020 Mar 5.
9
Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity.预计美国各州成年人肥胖和重度肥胖的流行率。
N Engl J Med. 2019 Dec 19;381(25):2440-2450. doi: 10.1056/NEJMsa1909301.
10
Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease.代谢特征对非酒精性脂肪性肝病患者肝硬化和肝细胞癌风险的影响。
Hepatology. 2020 Mar;71(3):808-819. doi: 10.1002/hep.31014. Epub 2020 Feb 26.